Zydus Launches Aerolife Mini™ to Simplify Inhaler Use
Ahmedabad, 19 March, 2026 – Zydus Lifesciences Limited, an innovation-led life-sciences company, has launched Aerolife Mini™, a next-generation pMDI (pressurised Metered-Dose Inhaler) enhancer. The launch marks India's first foldable, portable, and foldable spacer, designed to simplify inhaler use for patients with asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis.Zydus has launched Aerolife Mini™ under an exclusive licensing arrangement with AeroDel Technology Innovations Pvt. Ltd. The device is intended to improve drug deposition, enhance patient compliance, and provide greater convenience. Real-world studies indicate that suboptimal inhaler technique affects nearly 94% of patients. Aerolife Mini™ addresses this issue through its compact and ready-to-use design, offering a solution to the bulky form factors and assembly requirements of conventional spacer devices.
This initiative aligns with Zydus' strategy of building innovation-led, sustainable respiratory franchises focused on patient-centric drug device solutions. The company employs over 29,000 people worldwide, including 1,500 scientists engaged in R&D.
About Zydus Lifesciences Limited
Zydus Lifesciences Ltd. focuses on empowering people with freedom to live healthier and more fulfilled lives. The company develops and markets a broad range of healthcare therapies and aspires to transform lives through pathbreaking discoveries.
About AeroDel Technology Innovations Pvt. Ltd.
AeroDel develops and manufactures patient-centric respiratory devices focused on improving access to care in India and other global markets. AeroDel is supported by Venture Center, the Department of Science and Technology, Government of India, AIC-CCMB, and the Startup India Seed Fund.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.